Just last month, Johnson & Johnson forked out almost $100 million upfront as part of a $1.7 billion licensing deal for LegoChem’s LCB84, a Trop2-targeting ADC in phase 1/2 clinical testing that ...
The results of a phase 2 trial of MSD’s ROR1 inhibitor zilovertamab vedotin (zilo-V) back up the company's decision to push the antibody-drug conjugate (ADC) into a phase 3 programme.
One pipeline is built around antibody–drug conjugate (ADC) technology, of which the most advanced asset, ABL202, is being codeveloped in partnership with LegoChem Biosciences. Other pipelines ...
On the ADC front, ABL has partnered with LegoChem Biosciences (141080 under the Korean Securities Dealers Automated Quotations market) to codevelop cancer therapeutics with high linker stability ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback